PD-L1 Antikörper (AA 39-191)
-
- Target Alle PD-L1 Antikörper anzeigen
- PD-L1 (CD274 (PD-L1))
-
Bindungsspezifität
- AA 39-191
-
Reaktivität
- Human
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser PD-L1 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), ELISA, Coating (Coat)
- Spezifität
- Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20 % and 15 % identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases.
- Kreuzreaktivität (Details)
- Human. Mouse.
- Aufreinigung
- 1.0mg/ml of Ab purified from Bioreactor by Protein A/G.
- Immunogen
- Recombinant fragment of human CD274 protein (around aa39-191) (exact sequence is proprietary)
- Klon
- PDL1-2744
- Isotyp
- IgG1 kappa
- Top Product
- Discover our top product PD-L1 Primärantikörper
-
-
- Applikationshinweise
-
Known_Application: ELISA (For coating, order antibody without BSA),Western Blot (1-2 μg/mL),Optimal dilution for a specific application should be determined.
Positive_Control: Jurkat, HEK293 or HepG2 cells. Lung SqCC, Cervical or Breast Carcinoma.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Konzentration
- 1.0 mg/mL
- Buffer
- Prepared in 10 mM PBS, WITHOUT BSA and Azide.
- Konservierungsmittel
- Azide free
- Lagerung
- -20 °C,-80 °C
- Informationen zur Lagerung
- Antibody without azide store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous.
- Haltbarkeit
- 24 months
-
- Target
- PD-L1 (CD274 (PD-L1))
- Andere Bezeichnung
- CD274 (PD-L1 Produkte)
- Synonyme
- B7-H antikoerper, B7H1 antikoerper, PD-L1 antikoerper, PDCD1L1 antikoerper, PDCD1LG1 antikoerper, PDL1 antikoerper, A530045L16Rik antikoerper, B7h1 antikoerper, Pdcd1l1 antikoerper, Pdcd1lg1 antikoerper, Pdl1 antikoerper, RGD1566211 antikoerper, CD274 molecule antikoerper, CD274 antigen antikoerper, programmed cell death 1 ligand 2 antikoerper, CD274 antikoerper, Cd274 antikoerper, PDCD1LG2 antikoerper
- Hintergrund
-
B7 homolog 1, B7-H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, Programmed cell death 1 ligand 1,PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target)
Cellular localisation: Cell Surface and Cytoplasmic - Molekulargewicht
- 37-50kDa
- Gen-ID
- 29126, 521989
- UniProt
- Q9NZQ7
- Pathways
- Cancer Immune Checkpoints
-